The China-based contract research, development and manufacturing organization, or CRDMO, has agreed to sell the plant to Merck (NYSE:MRK) for around $500M, according to Reuters. In late December ...

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech that spans ...

Merck & Co has quietly added another drug to its immuno-oncology pipeline via an agreement with China's Sichuan Kelun Pharmaceutical, and is keeping the details close to its chest. The US pharma ...

Per the deal terms, Merck (NYSE:MRK) will receive exclusive rights to develop, manufacture, and commercialize HRS-5346 globally except in Greater China. In exchange, the Rahway, New Jersey-based ...

Recently, Hong Chow, Executive Vice President of Merck and Head of China & International for Merck Healthcare, led a delegation on the first "China Visit" of 2025, reaffirming that collaboration ...